This site is intended for healthcare professionals
News

Phase II DESTINYLung01 trial positive for Enhertu/Enhurtu in HER2 mutant NSCLC.- Daiichi Sankyo and AstraZeneca.

Read time: 1 mins
Last updated:2nd Jun 2020
Published:2nd Jun 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register free for full access to medthority.com